Dupuytrens 疾病治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

2023 年，全球掌腱膜挛缩症治疗市场价值约为8.894 亿美元，预计2024 年至2032 年复合年增长率为12.2%。性手部畸形，影响手部下方的组织层。随着时间的推移，组织结会形成，形成一条粗绳，可以弯曲一根或多根手指。掌腱膜挛缩症的盛行率不断上升，大大推动了市场的发展。药物输送技术的进步和老年人口的不断增长进一步促进了市场的成长。近年来，掌腱膜挛缩症的治疗取得了重大进展，明显转向更有效、侵入性更小的治疗方法，支持了其普及性和市场成长。

整个掌腱膜挛缩症治疗行业根据类型、治疗方法、配销通路和地区进行分类。

按类型细分，掌腱膜挛缩症治疗市场包括 I 型、II 型和 III 型。预测表明，到 2032 年，II 型细分市场将达到 13 亿美元。 II 型作为最常见的疾病形式引领市场，充当较温和的 I 型和较严重的 III 型之间的中介。随着 II 型手指挛缩变得更加明显，患者更有可能寻求医疗干预，从而推动了治疗需求。胶原酶注射或手术等治疗方法在 II 型阶段最有效，可促进收入成长。

按治疗方法细分，掌腱膜挛缩症治疗市场包括胶原蛋白酶注射剂、类固醇、免疫调节剂和其他治疗方法。 2023年，胶原酶注射剂的市占率为4.892亿美元。胶原酶注射提供了一种微创解决方案，将酶注射到受影响的胶原索中，无需进行手术切割。这种酵素会分解导致挛缩的胶原索，改善手指伸展和手部功能。胶原蛋白酶注射可以同时治疗多个手指或关节，使其成为广泛挛缩患者的灵活选择，从而推动市场成长。

在对医疗治疗研发 (R&D) 和创新的大力关注的推动下，德国掌腱膜挛缩症治疗市场预计到 2032 年将达到 2.344 亿美元。德国重视研发，拥有顶尖製药公司和知名研究机构，密切合作，推动药物开发和治疗掌腱膜挛缩症手术技术的突破。这些机构受益于完善的医疗基础设施和尖端技术，能够不断探索新的治疗方法，例如微创手术和生物疗法。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 掌腱膜挛缩症盛行率增加
    • 药物传输技术的进步
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 研发成本高
    • 潜在的副作用和併发症
• 成长潜力分析
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 2023 年定价分析
  • 按地区
  • 按关键人物
• 未来市场趋势
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• Ⅰ型
• II型
• Ⅲ型

第 6 章：市场估计与预测：按治疗方法，2021 - 2032 年

• 主要趋势
• 胶原蛋白酶注射液
• 类固醇
• 免疫调节剂
• 其他疗法

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 零售药房
• 医院药房
• 网路药房

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 北美洲
  • 我们
  • 加拿大
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AstraZeneca PLC
• Actiza Pharmaceutical Private Limited
• Bayer AG.
• Bristol-Meyers Squibb Company
• Endo International plc
• Fresenius SE and Co. KGaA
• Fortress Biotech, Inc.
• GSK plc
• Hikma Pharmaceuticals PLC
• Johnson and Johnson
• Merck and Co., Inc.
• Nantong Jinghua Pharmaceutical Co., Ltd
• Novartis AG
• LEO Pharma A/S
• Pfizer Inc.

The Global Dupuytren's Disease Therapeutics Market was valued at approximately USD 889.4 million in 2023 and projections indicate a growth rate of 12.2% CAGR from 2024 to 2032. Dupuytren's disease, also known as Dupuytren's contracture, is a progressive hand deformity affecting a tissue layer beneath the palm's skin. Over time, tissue knots form, leading to a thick cord that can bend one or more fingers. The increasing prevalence of Dupuytren's disease significantly drives the market. Advancements in drug delivery technologies and a growing geriatric population further bolster market growth. Recent years have seen significant strides in Dupuytren's disease therapeutics, with a clear shift towards treatments that are both more effective and less invasive, supporting their popularity and market growth.

The overall dupuytrens disease therapeutics industry is classified based on the type, therapeutics, distribution channel and region.

Segmented by type, the Dupuytren's disease therapeutics market includes type I, type II, and type III. Projections indicate the type II segment will reach USD 1.3 billion by 2032. Type II leads the market as the most common form of the disease, acting as an intermediary between the milder type I and the more severe type III. As finger contracture becomes more evident in type II, patients are more likely to seek medical intervention, driving treatment demand. Treatments like collagenase injections or surgery are most effective during the type II stage, enhancing revenue growth.

Segmented by therapeutics, the Dupuytren's disease therapeutics market includes collagenase injections, steroids, immune-modulators, and other treatments. In 2023, collagenase injections made up USD 489.2 million of the market. Collagenase injections offer a minimally invasive solution, injecting the enzyme into the affected collagen cords and eliminating the need for surgical cuts. This enzyme breaks down the collagen cords causing contractures, improving finger extension and hand function. Collagenase injections can address multiple fingers or joints at once, making it a flexible choice for patients with widespread contractures, thus propelling market growth.

Germany's Dupuytren's disease therapeutics market is set to reach USD 234.4 million by 2032, driven by a strong focus on research and development (R&D) and innovations in medical treatments. Germany emphasizes R&D, hosting top-tier pharmaceutical firms and renowned research institutions that collaborate closely to drive breakthroughs in both drug development and surgical techniques for treating Dupuytren's disease. These institutions benefit from well-established healthcare infrastructure and access to cutting-edge technology, enabling the continuous exploration of new treatment methods, such as minimally invasive procedures and biologic therapies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence for dupuytren's disease
    • 3.2.1.2 Advancements in drug delivery technologies
    • 3.2.1.3 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High research and development cost
    • 3.2.2.2 Potential side effects and complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Pipeline analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Type I
• 5.3 Type II
• 5.4 Type III

Chapter 6 Market Estimates and Forecast, By Therapeutics, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Collagenase injection
• 6.3 Steroids
• 6.4 Immune-modulators
• 6.5 Other therapeutics

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Retail pharmacy
• 7.3 Hospital pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Europe
  • 8.2.1 Germany
  • 8.2.2 UK
  • 8.2.3 France
  • 8.2.4 Spain
  • 8.2.5 Italy
  • 8.2.6 Netherlands
  • 8.2.7 Rest of Europe
• 8.3 North America
  • 8.3.1 U.S.
  • 8.3.2 Canada
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca PLC
• 9.2 Actiza Pharmaceutical Private Limited
• 9.3 Bayer AG.
• 9.4 Bristol-Meyers Squibb Company
• 9.5 Endo International plc
• 9.6 Fresenius SE and Co. KGaA
• 9.7 Fortress Biotech, Inc.
• 9.8 GSK plc
• 9.9 Hikma Pharmaceuticals PLC
• 9.10 Johnson and Johnson
• 9.11 Merck and Co., Inc.
• 9.12 Nantong Jinghua Pharmaceutical Co., Ltd
• 9.13 Novartis AG
• 9.14 LEO Pharma A/S
• 9.15 Pfizer Inc.